P2RY12 and cancer: In routine clinical practice, it is common that physicians change the prescribed P2Y12 inhibitor (i.e. de-escalation/escalation) due to newly recognized medical conditions (e.g. cancer) or newly introduced medications (e.g. introduction of oral anticoagulation) during the course after index PCI.